MacroGenics (MGNX) Competitors $1.62 -0.11 (-6.36%) Closing price 04:00 PM EasternExtended Trading$1.65 +0.03 (+1.79%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MGNX vs. INBX, UPXI, YMAB, PRTC, CGEM, AURA, FULC, ADCT, AUTL, and DMACShould you be buying MacroGenics stock or one of its competitors? The main competitors of MacroGenics include Inhibrx Biosciences (INBX), Upexi (UPXI), Y-mAbs Therapeutics (YMAB), PureTech Health (PRTC), Cullinan Therapeutics (CGEM), Aura Biosciences (AURA), Fulcrum Therapeutics (FULC), ADC Therapeutics (ADCT), Autolus Therapeutics (AUTL), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical products" industry. MacroGenics vs. Its Competitors Inhibrx Biosciences Upexi Y-mAbs Therapeutics PureTech Health Cullinan Therapeutics Aura Biosciences Fulcrum Therapeutics ADC Therapeutics Autolus Therapeutics DiaMedica Therapeutics Inhibrx Biosciences (NASDAQ:INBX) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment. Do analysts prefer INBX or MGNX? MacroGenics has a consensus target price of $3.60, suggesting a potential upside of 122.22%. Given MacroGenics' stronger consensus rating and higher probable upside, analysts clearly believe MacroGenics is more favorable than Inhibrx Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibrx Biosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00MacroGenics 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Which has more volatility and risk, INBX or MGNX? Inhibrx Biosciences has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500. Comparatively, MacroGenics has a beta of 1.63, meaning that its share price is 63% more volatile than the S&P 500. Does the media prefer INBX or MGNX? In the previous week, MacroGenics had 8 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 10 mentions for MacroGenics and 2 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 1.78 beat MacroGenics' score of 0.42 indicating that Inhibrx Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive MacroGenics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings & valuation, INBX or MGNX? Inhibrx Biosciences has higher earnings, but lower revenue than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInhibrx Biosciences$200K1,998.24$1.69B-$10.58-2.61MacroGenics$149.96M0.68-$66.97M-$0.57-2.84 Do institutionals and insiders hold more shares of INBX or MGNX? 82.5% of Inhibrx Biosciences shares are held by institutional investors. Comparatively, 96.9% of MacroGenics shares are held by institutional investors. 17.1% of Inhibrx Biosciences shares are held by company insiders. Comparatively, 13.0% of MacroGenics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is INBX or MGNX more profitable? Inhibrx Biosciences has a net margin of 0.00% compared to MacroGenics' net margin of -21.99%. MacroGenics' return on equity of -40.24% beat Inhibrx Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Inhibrx BiosciencesN/A -137.83% -76.31% MacroGenics -21.99%-40.24%-14.62% SummaryMacroGenics beats Inhibrx Biosciences on 11 of the 17 factors compared between the two stocks. Get MacroGenics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGNX vs. The Competition Export to ExcelMetricMacroGenicsMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$109.35M$10.82B$5.79B$10.40BDividend YieldN/A1.88%5.63%4.60%P/E Ratio-2.8421.2676.4826.75Price / Sales0.6832.26531.95124.23Price / CashN/A24.5037.9261.55Price / Book0.883.4213.726.40Net Income-$66.97M$210.63M$3.29B$271.62M7 Day Performance1.89%-0.02%1.03%2.85%1 Month Performance8.72%2.67%6.32%9.64%1 Year Performance-52.21%-9.96%81.16%31.62% MacroGenics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGNXMacroGenics4.4539 of 5 stars$1.62-6.4%$3.60+122.2%-47.6%$109.35M$149.96M-2.84430News CoverageAnalyst UpgradeINBXInhibrx Biosciences1.1406 of 5 stars$27.18-1.2%N/A+56.9%$398.64M$200K-2.57166Positive NewsUPXIUpexi3.0867 of 5 stars$6.33-6.4%$15.50+144.9%+62.4%$397.79M$26M0.00130YMABY-mAbs Therapeutics1.803 of 5 stars$8.61+0.2%$9.62+11.8%N/A$390.31M$85.39M-17.22150Positive NewsPRTCPureTech Health0.6485 of 5 stars$15.39-4.3%N/A-22.8%$388.63M$4.83M0.00100Positive NewsShort Interest ↑Gap UpCGEMCullinan Therapeutics2.1273 of 5 stars$6.35-2.8%$27.67+335.7%-63.2%$385.76MN/A-1.9730Positive NewsAnalyst UpgradeAURAAura Biosciences1.4111 of 5 stars$5.97-3.4%$22.00+268.5%-34.5%$383.90MN/A-3.0550FULCFulcrum Therapeutics2.3955 of 5 stars$7.07+1.0%$9.60+35.8%+119.2%$378.64M$80M-5.80100Positive NewsADCTADC Therapeutics2.7943 of 5 stars$3.21-3.2%$7.75+141.8%+9.9%$372.37M$70.84M-2.04310Positive NewsAUTLAutolus Therapeutics3.7458 of 5 stars$1.32-4.3%$9.12+590.9%-64.9%$367.28M$29.93M-1.57330Positive NewsShort Interest ↓DMACDiaMedica Therapeutics2.0392 of 5 stars$7.01-1.1%$12.33+75.9%+63.7%$366.48MN/A-10.1620 Related Companies and Tools Related Companies Inhibrx Biosciences Alternatives Upexi Alternatives Y-mAbs Therapeutics Alternatives PureTech Health Alternatives Cullinan Therapeutics Alternatives Aura Biosciences Alternatives Fulcrum Therapeutics Alternatives ADC Therapeutics Alternatives Autolus Therapeutics Alternatives DiaMedica Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGNX) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MacroGenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MacroGenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MGNX Stock Alerts